Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million to add a preclinical targeted protein degrader aimed at MLLT1/3 and other oncology targets. The deal brings Amgen a degrader program intended for acute myeloid leukemia and other hematologic malignancies that showed preclinical anti‑cancer activity and mechanistic differentiation from existing therapies. Amgen said the acquisition complements its protein‑degradation strategy and early oncology investments. Dark Blue, an Oxford University spinout, will be integrated into Amgen’s research organization as Amgen seeks to accelerate first‑in‑human development and combinations in leukemia indications.